Free beta — full access, free until October 2026. No card, no auto-charge — paid plans are opt-in when they launch.
Company
Regenicin, Inc. (0001412659)
Standardized SEC financial data for Regenicin, Inc. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001412659 · Surgical & Medical Instruments & Apparatus.
Return on equity
12.4%
Free cash flow
-$27K
Current ratio
0.02×
Income statement
USD
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
R&D expense
$1K
$5K
—
—
—
—
SG&A expense
$1.1M
$971K
$789K
$706K
$636K
$601K
Operating income
-$780K
-$961K
-$540K
-$737K
-$511K
-$636K
Interest expense
-$18K
$17K
$19K
$18K
-$35K
-$36K
Pretax income
-$1.1M
—
—
—
—
—
Net income
$1.1M
-$974K
-$630K
-$829K
-$741K
-$692K
Standardized from Regenicin, Inc.'s SEC filings — per-share figures split-adjusted. Full history via the API.